Stock Analiz

Creative Medical Technology Holdings, Inc. CELZ

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$0.53Market cap $4M
Open the interactive analysis →

Creative Medical Technology Holdings, Inc. (CELZ) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to September 30, 2026 it had revenue of $3000 and net income of -$7M, a net margin of -249160.1%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -48% a year, a 5-year average ROIC of -64%.

About Creative Medical Technology

Creative Medical Technology is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $4800 in 2017 to $6000 in 2025, growth of about 2.8% a year. It was profitable in 1 of the last 10 years in our data. Its share count fell by 78% over three years (buybacks). It spends 37663% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health4/5
Shareholder returns1/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1,337.0
P/B0.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-162.6%
Shareholder yield0.2%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-45.5%
Revenue growth (5 yrs, per year)-48.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-55011.6%
ROIC (5-yr avg.)-64.4%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$3000$6000$11000$9000$88600—$164500$165500$124400$4800$0
Net income-$7M-$6M-$5M-$5M-$10M$19M-$36M-$8M-$14M-$3M-$766072
Free cash flow-$7M—————-$434556-$1M-$1M-$889621-$445232
EPS (diluted)$-1.99$-2.52$-3.71$-3.76$-0.93$5.61$-62.69$-0.82$-3.50$-4.50$-1.50
Net margin-249160.1%-99916.8%-49940.7%-58739.7%-11449.3%—-22082.2%-5126.1%-10977.2%-55398.1%—
ROIC—-81.7%-90.6%-54.3%-64.6%-30.6%—————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $20.00, 3687% above the current price; targets range from $20.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-1.56 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Creative Medical Technology pay a dividend?

Not currently.

Is Creative Medical Technology a good stock to buy?

We do not give buy or sell advice. Creative Medical Technology scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.